Colorectal cancer (CRC) is the second deadliest cancer in the U.S. However, millions of eligible Americans do not get screened due to a lack of access to or avoidance of invasive screening options like colonoscopies. The rates of CRC incidence among younger populations under 50 years old is also on the rise. ColoSense, Geneoscopy's FDA-approved at home screening test indicated for adults, ages 45 and over, who are at a typical risk for developing CRC, uses an innovative and proprietary RNA-based platform to screen for CRC and advanced adenomas. Learn more at: https://bit.ly/3W9RfH7
Geneoscopy
Biotechnology Research
St. Louis, MO 5,940 followers
Cancer Prevention | Diagnostics | Precision Medicine
About us
Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.
- Website
-
http://geneoscopy.com
External link for Geneoscopy
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- St. Louis, MO
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Life Sciences, Noninvasive Diagnostic Screening, Colorectal Cancer Screening, GI Health, GI Disease Companion Diagnostics, seRNA, RNA Biomarkers, Precision Medicine Partnerships, and IBD
Locations
-
Primary
2220 Welsch Industrial Ct
St. Louis, MO 63146, US
Employees at Geneoscopy
-
Katherine Tynan
-
Richard Roberts
Senior Scientist
-
Jim Fitzgibbon
Vice President, Business Development and Pharma Partnering
-
Dave Messina
Founder/COO @ Cofactor Genomics, GP Bio Health Fund and SVP @ Pioneer Fund, Y Combinator, Human Genome Project, TechBio Founder using RNA Machine…
Updates
-
We are excited to share that Geneoscopy has received the St. Louis INNO's Fire Award! The Fire Awards recognize innovators shaping the entrepreneurial ecosystem and applaud companies and organizations growing their teams, launching new products, and positively impacting society and the community. We are honored to be acknowledged for our commitment to advancing gastrointestinal health through pioneering solutions like ColoSense™, our noninvasive RNA biomarker colorectal cancer screening test. Congratulations to all the Fire Award winners and nominees. We are thankful to be a part of such an amazing community. We extend our gratitude to St. Louis Inno and sponsors, Anders CPAs Advisors, Arch Grants and Greater St. Louis, Inc., as well as our dedicated team, partners, and supporters, for believing in our mission. #INNOFireAwards #HealthcareInnovation #Geneoscopy #ColorectalCancer #STLMade
-
FOR IMMEDIATE RELEASE: Geneoscopy is pleased to announce the publication of a study in The Journal of Molecular Diagnostics, highlighting the analytical validation of ColoSense, a noninvasive, multi-target stool RNA (mt-sRNA) screening test for colorectal cancer and advanced adenomas in average-risk individuals aged 45 and older. This study highlights ColoSense's high stability, precision, and reproducibility. Read the full release here: https://bit.ly/4cAIA66
-
Dr. Kimmie Ng, Associate Professor of Medicine at Harvard Medical School and Founding Director of Dana-Farber Cancer Institute's Young-Onset Colorectal Cancer Center, discusses the increase in colorectal cancer among those under 50 and emphasizes the need for awareness, early detection, and proactive healthcare strategies. Learn more: https://bit.ly/4eR7wb9
Harvard's Kimmie Ng discusses the rise in colorectal rates among younger people
https://www.youtube.com/
-
Happy 4th of July from Geneoscopy! As we celebrate our nation's independence, let's also celebrate the freedom to live vibrant and healthy lives. Early detection through colorectal cancer screening can help ensure brighter tomorrows for all. Enjoy the festivities, stay safe, and take care of yourself and your loved ones! #IndependenceDay #Wellness #GeneoscopyCares
-
Exciting news! The Crohn's & Colitis Foundation unveiled its new five-year research agenda, a strategic roadmap developed to set research priorities in inflammatory bowel disease (IBD) not only for the Foundation, but for the entire IBD research community. Read the latest: https://bit.ly/4cBIvif Beyond colorectal cancer, Geneoscopy, in partnership with leading universities and biopharmaceutical companies, is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas, including IBD. We're committed to improving patient outcomes and driving progress in IBD diagnostics. Learn more about our work: https://bit.ly/3VHRuJl #Geneoscopy #IBDResearch #HealthcareInnovation #CrohnsDisease #UlcerativeColitis #RNABiomarker@
-
Listen in as Chief Medical and Science Officer Dr. Erica Barnell shares details about ColoSense, Geneoscopy's FDA-approved noninvasive colorectal cancer screening test and how the company is leveraging our proprietary, patented stool-based RNA biomarker technology to empower patients and providers to transform gastrointestinal health through innovative diagnostics. GI Oncology Now #RNABiomarkers #ColorectalCancerScreening #FDA #publichealth #closethegap
🧬 We spoke with Erica Barnell of Geneoscopy on the recent FDA approval of ColoSense and how the test can aid in public health initiatives, as well as the rise of #colorectal cancer diagnoses in younger patients. 📺 Watch the full interview: https://buff.ly/3KRws4u
-
Healthcare professionals play an essential role in raising awareness, educating and encouraging patients to screen for colorectal cancer starting at age 45. If you're at average risk, talk to your provider about which screening option is right for you. Thank you to Lisa A. Hall, MHA, CDP, Senior Director of Prevention and Screening, with our allies in advocacy, Colorectal Cancer Alliance, and Cancer Nursing Today. https://lnkd.in/gB2nAY26 #ColorectalCancer #CancerScreening #HealthcareProfessionals
Colorectal Cancer: How Nurses Can Help Patients Understand Risks, Address Screening Barriers
https://www.youtube.com/
-
Today we honor the resilience and strength of the Black community in the face of adversity. Let's recognize the past and work towards a more inclusive future. #Juneteenth Read more about Juneteenth and ways you can honor this day: https://s.si.edu/45VahUm
-
On National Wear Blue Day, we are raising awareness for men's health by wearing blue. Show your support for the men in your lives and remind them to prioritize their health. Regular check-ups, health screenings, exercise, and a balanced diet are essential for maintaining overall well-being. Let's encourage our friends, family, and colleagues to take care of themselves. 💙 #MensHealth #WearBlueDay #HealthAwareness #Wellness #Prevention